AIM
EIGR

Acrospire Investment Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Acrospire Investment Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-168
Closed -$67K – 2465
2016
Q3 		$67K Buy
168
+135
+409% +$68.9K 0.04% 850
2016
Q2 		$20K Buy
+33
New +$20K 0.01% 1531

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acrospire Investment Management's EIGR Position: Q4 2016 in Review

Acrospire Investment Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2016, closing a stake of 168 shares — an estimated $67K sold.

Acrospire Investment Management first reported a position in EIGR in Q2 2016 and held it in 2 quarters. The position peaked at $67K in Q3 2016. 51 funds tracked by Wall St. Rank hold EIGR as of Q4 2016.

  • Acrospire Investment Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 168 Eiger BioPharmaceuticals, Inc. shares in Q4 2016, an estimated $67K.
  • Acrospire Investment Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Eiger BioPharmaceuticals, Inc. position peaked at $67K in Q3 2016.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2016.

Based on Acrospire Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.